Design Therapeutics, Inc.
DSGNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Design Therapeutics, Inc. (DSGN) is listed under Biotechnology. At a $785.1M market cap, Design Therapeutics, Inc. ranks as a small-cap company within healthcare. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
Market Cap
$785.1M
Beta
1.59
P/E (TTM)
—
P/E (Fwd)
-7.68
EPS (TTM)
$-1.20
EPS (Fwd)
$-1.64
ROE
-31.3%
ROA
-20.9%
Cash
$222.8M
Total Debt
$2.7M
Free CF
-$31.6M
52W Change
215.8%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $222.8M in cash comfortably exceeding the $2.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$31.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -31.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Design Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Design Therapeutics, Inc.'s trajectory.